• 1. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 2. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 3. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 4. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzyl halides Benzyl chlorides

Research Briefing on 1-(Chloromethyl)-4-[2-(2-methoxyethoxy)ethoxy]benzene (CAS: 314286-40-3) in Chemical Biology and Pharmaceutical Applications

The compound 1-(Chloromethyl)-4-[2-(2-methoxyethoxy)ethoxy]benzene (CAS: 314286-40-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This briefing synthesizes the latest findings on its synthesis, applications, and mechanistic insights, with a focus on its role as a versatile intermediate in drug development and chemical biology probes.

Recent studies highlight the compound's utility as a key building block in the synthesis of polyethylene glycol (PEG)-modified drug conjugates. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its efficacy in enhancing the solubility and bioavailability of hydrophobic anticancer agents through PEGylation. The chloromethyl group facilitates covalent linkage to active pharmaceutical ingredients (APIs), while the ethoxy side chains confer improved pharmacokinetic properties.

Structural analyses reveal that the unique ether-alkoxy architecture of 314286-40-3 enables precise control over molecular spacing in bioconjugates. Research from the ACS Chemical Biology (2024) illustrates its application in constructing pH-sensitive drug delivery systems, where the compound serves as a linker that undergoes cleavage in tumor microenvironments (pH 6.5-7.0). This property has been exploited in the development of targeted therapies for solid tumors.

Mechanistic studies using nuclear magnetic resonance (NMR) and mass spectrometry (MS) have elucidated the compound's stability profile. Data indicates exceptional resistance to enzymatic degradation in physiological conditions, making it particularly valuable for long-circulating therapeutics. However, researchers note that the chloromethyl group requires careful handling due to its reactivity with nucleophilic residues in proteins.

Emerging applications extend to proteolysis-targeting chimeras (PROTACs), where 314286-40-3 functions as a spacer between E3 ligase binders and target protein ligands. A 2024 Nature Chemical Biology study reported its superiority over traditional alkyl linkers in maintaining optimal distance (12-15 ?) for ternary complex formation, achieving 80% higher degradation efficiency for challenging targets like KRAS mutants.

Ongoing clinical trials (Phase I/II) incorporating this compound show promising results in reducing immunogenicity of biologic drugs. The extended PEG-like chain effectively masks antigenic epitopes while maintaining drug activity, addressing a critical challenge in biosimilar development. Safety assessments indicate favorable toxicological profiles at therapeutic doses.

Future research directions include exploration of its chiral derivatives for stereoselective drug delivery and adaptation for mRNA vaccine formulations. The compound's modular design allows for customization of chain length and terminal functionalization, positioning it as a platform technology for next-generation bioconjugates.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)